Hepatitis D
Drug research and approvals for hepatitis D: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 20 studies of hepatitis D are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 3
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting now
Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗- Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With…NCT07610772 · Phase 1 · Aarhus University Hospital · starts Apr 23, 2026
- A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear…NCT07499544 · Phase 3 · Huahui Health · starts Apr 22, 2026
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837 · Phase 2 / Phase 3 · Mirum Pharmaceuticals, Inc. · starts Feb 26, 2026
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DNCT07491848 · Not reported · Research Center of Periodontal-Systemic Interactions · starts Feb 15, 2026
- "Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.NCT07317011 · Not reported · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · starts Oct 1, 2025
- Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideNCT07429864 · Not reported · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Sep 24, 2025
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908 · Phase 3 · Mirum Pharmaceuticals, Inc. · starts Aug 27, 2025
- Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusNCT07096193 · Phase 1 / Phase 2 · Gilead Sciences · starts Jul 31, 2025
- Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East AustriaNCT06834178 · Not reported · Vanessa Stadlbauer-Koellner, MD · starts May 1, 2025
- HDV Screening StudyNCT06889805 · Not reported · Grace Lai Hung Wong · starts Feb 15, 2025
Drug pipeline
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indicationsPhase 3 6
- Peginterferon ALFA-2AInterferon alpha/beta receptor agonist
- LonafarnibProtein farnesyltransferase inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- Peginterferon LAMBDA-1AInterferon lambda receptor agonist
- Peginterferon ALFA-2BInterferon alpha/beta receptor agonist
- Tenofovir anhydrousHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
Phase 2 12 of 13
- Entecavir anhydrousDNA polymerase/reverse transcriptase inhibitor
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- BulevirtideBile acid transporter inhibitor
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- EzetimibeNiemann-Pick C1-like protein 1 inhibitor
- Ropeginterferon ALFA-2BInterferon alpha/beta receptor positive modulator
- Myrcludex bBile acid transporter inhibitor
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- TerfenadineHistamine H1 receptor antagonist
- UrsodiolBile acid receptor FXR agonist
- HepalatideBile acid transporter inhibitor
- Tobevibart
Phase 1 or earlier 1
- NivolumabProgrammed cell death protein 1 inhibitor
How its trials ended
85 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 39% met their primary endpoint, 11% missed it and 50% stopped early.
- Ongoing3440%
- Completed, result not reported2428%
- Status unknown911%
- Met its primary endpoint78%
- Stopped: other or unclear56%
- Stopped: sponsor or business decision34%
- Missed its primary endpoint22%
- Stopped: enrollment or feasibility11%
Trials authorized in Canada
Newest first; search them all in Canada trials| May 8, 2025 | A global, randomized, open-label, multicenter, phase 2b/3 trial evaluating BJT-778 vs delayed treatment for the treatment of chronic hepatitis delta infection…Brelovitug (BJT-778) | Mirum Pharmaceuticals | Ongoing |
| Mar 20, 2025 | A phase 3 randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy in participants with chronic hdv…Tobevibart (VIR-3434) / Elebsiran (VIR-2218) | Vir Biotechnology, Inc. | Ongoing |
| Mar 1, 2019 | A phase 3, matrix design, partially double-blind, randomized study of the efficacy and safety of 50 mg lonafarnib / 100 mg ritonavir bid with and without 180…Lonafarnib/ Ritonavir/ Peginterferon ALFA-2A | Eiger Biopharmaceuticals, Inc | Closed |
FDA orphan designations
Approved first, then open designations, newest first| May 22, 2026 | HepcludexTreatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis | Gilead Sciences, Inc. | Approved |
| Jun 14, 2012 | Interferon-alpha secreting autologous micro-organ tissue…Treatment of chronic hepatitis D | Medgenics, Inc. | Designated |
Medicines authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 31, 2020 | HepcludexBulevirtide · orphan | Gilead Sciences Ireland UC | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA